Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May;32(15):3845-54.
doi: 10.1016/j.biomaterials.2011.01.077. Epub 2011 Feb 26.

Reconstitutable charged polymeric (PLGA)(2)-b-PEI micelles for gene therapeutics delivery

Affiliations

Reconstitutable charged polymeric (PLGA)(2)-b-PEI micelles for gene therapeutics delivery

Deepa Mishra et al. Biomaterials. 2011 May.

Abstract

This study investigated the potential of creating a charged polymeric micelle-based nucleic acid delivery system that could easily be reconstituted by the addition of water. (PLGA(36kDa))(2)-b-bPEI(25kDa) (PLGA MW 36 kDa, bPEI M(w) 25 kDa, PLGA:bPEI block ratio = 2) was synthesized and used to prepare cationic micelles. The copolymer retained proton-buffering capability from the bPEI block within the endosomal pH range. Micelle/pDNA complexes retained their particle size (100-150 nm) and surface charge (30-40 mV) following reconstitution. It was found that adding a small amount of low molecular weight bPEI (1.8 kDa) completely shielded pDNA in the micelle/pDNA complexes and enhanced transfection efficiency 50-100 fold for both fresh and reconstituted complexes without affecting complex size. Transfection efficiency for "reconstituted" micelle/pDNA/bPEI(1.8kDa) (WR 1) complexes was 16-fold higher than its "fresh" counterpart. Although transfection levels achieved using "reconstituted" micelle/pDNA/bPEI(1.8kDa) complexes were 3.6-fold lower than control "fresh" bPEI(25kDa)/pDNA (N/P 5) complexes, transfection levels were 39-fold higher than "reconstituted" bPEI(25kDa)/pDNA (N/P 5) complexes. The micelle/pDNA/bPEI(1.8kDa) system showed very low cytotoxicity in MCF7 cells even with pDNA doses up to 20 μg, and transfection levels increased linearly with increasing pDNA dose. These results indicate that this PLGA-b-bPEI polymeric micelle-based system is well suited as a reconstitutable gene delivery system, and has high potential for use as a delivery system for gene therapy applications.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(a) Reaction schematic for (PLGA36kDa)2-b-bPEI25kDa copolymer and (b) schematic representation of the structures of (PLGA36kDa)2-b-bPEI25kDa micelles, micelle/pDNA complexes, and micelle/pDNA/bPEILMW complexes.
Fig. 2
Fig. 2
Particle size and surface charge of (PLGA36kDa)2-b-bPEI25kDa micelles before and after reconstitution. (n=5; mean ± SD)
Fig. 3
Fig. 3
Proton buffering capacity of (PLGA36kDa)2-b-bPEI25kDa micelles and bPEI25kDa. (n=3; mean ± SD)
Fig. 4
Fig. 4
Cytotoxicity of (PLGA36kDa)2-b-bPEI25kDa micelles, bPEI25kDa, and bPEI1.8kDa in MCF7 cells. (n=6; mean ± SD)
Fig. 5
Fig. 5
Surface shielding effect of bPEI1.8kDa on gene condensation of micelle/pDNA complexes: (a) agarose gel retardation and (b) dye quenching assay (n=3; mean ± SD).
Fig. 6
Fig. 6
Particle size and surface charge of micelle/pDNA complexes and micelle/pDNA/bPEI1.8kDa complexes before and after reconstitution. (n=5; mean ± SD)
Fig. 7
Fig. 7
Transfection efficiency of fresh and reconstituted micelle/pDNA/bPEI1.8kDa complexes (1 μg of pDNA) in MCF7 cells (5×105 cells at seeding). (n=8; mean ± SD)
Fig. 8
Fig. 8
Cytotoxicity of fresh and reconstituted micelle/pDNA/bPEI1.8kDa complexes (0.5 μg of pDNA) in MCF7 cells (2.5×105 cells at seeding). (n=4; mean ± SD)
Fig. 9
Fig. 9
Cellular uptake of “fresh” and “reconstituted” micelle/pDNA/bPEI1.8kDa (WR 1) and “fresh” bPEI25kDa/pDNA (N/P 5) complexes in MCF7 cells.
Fig. 10
Fig. 10
pDNA-dose dependent transfection characteristics of “reconstituted” micelle/pDNA/bPEI1.8kDa (WR 1) complexes: (a) transfection efficiency in MCF7 cells (5×105 cells at seeding) and (b) cytotoxicity in MCF7 cells (2.5×105 cells at seeding). (n=4; mean ± SD)

Similar articles

Cited by

References

    1. Louis A, Bartke A, Masternak MM. Effects of growth hormone and thyroxine replacement therapy on insulin signaling in Ames Dwarf mice. J Gerontol A Biol Sci Med Sci. 2010;65:344–352. - PMC - PubMed
    1. Pawlyk BS, Bulgakov OV, Liu X, Xu X, Adamian M, Sun X, et al. Replacement gene therapy with a human RPGRIP1 sequence slows photoreceptor degeneration in a murine model of leber congenital amaurosis. Hum Gene Ther. 2010;21:993–1004. - PMC - PubMed
    1. Wang G, Qiu J, Wang R, Krause A, Boyer JL, Hackett NR, et al. Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther. 2010;17:559–570. - PMC - PubMed
    1. Zhou S, Mody D, DeRavin SS, Hauer J, Lu T, Ma Z, et al. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood. 2010;116:900–908. - PMC - PubMed
    1. López-Fraga M, Wright N, Jiménez A. RNA interference-based therapeutics: new strategies to fight infectious disease. Infect Disord Drug Targets. 2008;8:262–273. - PubMed

Publication types